These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31217352)

  • 1. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
    Wang S; Mondal S; Zhao C; Berishaj M; Ghanakota P; Batlevi CL; Dogan A; Seshan VE; Abel R; Green MR; Younes A; Wendel HG
    JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
    Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
    Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
    N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Means and Challenges in the Targeting of BTK.
    Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
    Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
    Gu D; Tang H; Wu J; Li J; Miao Y
    J Hematol Oncol; 2021 Mar; 14(1):40. PubMed ID: 33676527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
    Estupiñán HY; Wang Q; Berglöf A; Schaafsma GCP; Shi Y; Zhou L; Mohammad DK; Yu L; Vihinen M; Zain R; Smith CIE
    Leukemia; 2021 May; 35(5):1317-1329. PubMed ID: 33526860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of BTK inhibitors for the treatment of B-cell malignancies.
    Kim HO
    Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of quinoline-based irreversible BTK inhibitors.
    de Bruin G; Demont D; de Zwart E; Verkaik S; Hoogenboom N; van de Kar B; van Lith B; Emmelot-van Hoek M; Gulrajani M; Covey T; Kaptein A; Barf T
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127261. PubMed ID: 32527559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
    Gomez EB; Ebata K; Randeria HS; Rosendahl MS; Cedervall EP; Morales TH; Hanson LM; Brown NE; Gong X; Stephens J; Wu W; Lippincott I; Ku KS; Walgren RA; Abada PB; Ballard JA; Allerston CK; Brandhuber BJ
    Blood; 2023 Jul; 142(1):62-72. PubMed ID: 36796019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
    Sun Y; Zhao X; Ding N; Gao H; Wu Y; Yang Y; Zhao M; Hwang J; Song Y; Liu W; Rao Y
    Cell Res; 2018 Jul; 28(7):779-781. PubMed ID: 29875397
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
    Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
    Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
    Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.
    Zain R; Vihinen M
    Front Immunol; 2021; 12():694853. PubMed ID: 34349760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors.
    Cancer Discov; 2022 May; 12(5):1179. PubMed ID: 35491639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.